Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Designed solely for parenteral use (drug administration by intravenous, intramuscular, or subcutaneous injection) following the addition of drugs that require dilution or
The 2013 Leggett paper used a GHRH-receptor-targeted botulinum-neurotoxin construct to further characterise pulsatile-secretion mechanisms (PMID 23825127)
Specific compatibility considerations include confirmation of absence of reducing agents for disulphide-containing peptides, BSA carrier supplementation for recombinant proteins, and acetic acid acidification for hydrophobic peptides requiring low pH solubilisation
Sources Innerbody uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles
US$ 27.28
US$ 25.75
US$ 21.51
.png)
US$ 23.86
